Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Not Confirmed
Not Confirmed
24-27 July, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
24-25 July, 2025
BIO Asia-TaiwanBIO Asia-Taiwan
Industry Trade Show
Not Confirmed
24-27 July, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
25 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/senhwa-biosciences-highlights-breakthroughs-in-dual-first-in-class-drug-programs-at-annual-shareholders-meeting-today-302490615.html
02 Apr 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-positive-clinical-data-from-phase-1expansion-trial-of-silmitasertib-cx-4945-in-the-treatment-of-basal-cell-carcinoma-302418218.html
01 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-the-appointment-of-dr-yiu-lian-fong-the-former-global-head-of-janssen-diagnostic-innovation-and-rd-at-johnson--johnson-as-the-new-corporate-director-302293919.html
14 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/us-fda-issues-study-may-proceed-letter-for-the-pilot-study-of-pidnarulex-pharmacodynamics-in-patients-with-advanced-solid-tumors-sponsored-by-the-us-national-cancer-institute-302274665.html
17 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/senhwa-biosciences-announces-ind-submission-to-us-fda-for-pilot-study-of-pidnarulex-pharmacodynamics-in-patients-with-advanced-solid-tumors-sponsored-by-nci-302251175.html
12 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/us-fda-grants-rpd-designation-to-senhwa-biosciences-silmitasertib-for-pediatric-neuroblastoma-302247466.html
Details:
CX-4945 (silmitasertib) is a first-in-class small molecule drug that acts as a CK2 inhibitor. It is being evaluated for the treatment of basal cell carcinoma.
Lead Product(s): Silmitasertib
Therapeutic Area: Oncology Brand Name: CX-4945
Study Phase: Phase IProduct Type: Cytotoxic Drug
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 02, 2025
Lead Product(s) : Silmitasertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Senhwa Reports Positive Phase 1 Data for Silmitasertib in Carcinoma
Details : CX-4945 (silmitasertib) is a first-in-class small molecule drug that acts as a CK2 inhibitor. It is being evaluated for the treatment of basal cell carcinoma.
Product Name : CX-4945
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 02, 2025
Details:
CX-4945 (silmitasertib) is a first-in-class small molecule drug that acts as a CK2 inhibitor. It is being evaluated for the treatment of pediatric neuroblastoma.
Lead Product(s): Silmitasertib,Irinotecan Hydrochloride,Temozolomide
Therapeutic Area: Oncology Brand Name: CX-4945
Study Phase: Phase I/ Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 09, 2024
Lead Product(s) : Silmitasertib,Irinotecan Hydrochloride,Temozolomide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants RPD Designation to Senhwa Bio’ Silmitasertib for Pediatric Neuroblastoma
Details : CX-4945 (silmitasertib) is a first-in-class small molecule drug that acts as a CK2 inhibitor. It is being evaluated for the treatment of pediatric neuroblastoma.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 09, 2024
Details:
Pidnarulex (CX-5461) is a first-in-class small-molecule designed to stabilize G4 structures, it induces DNA damage and promotes cancer cell death, holding a great potential for various cancers.
Lead Product(s): Pidnarulex
Therapeutic Area: Oncology Brand Name: CX-5461
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 14, 2024
Lead Product(s) : Pidnarulex
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Issues Approval for Pidnarulex Study in Advanced Solid Tumors
Details : Pidnarulex (CX-5461) is a first-in-class small-molecule designed to stabilize G4 structures, it induces DNA damage and promotes cancer cell death, holding a great potential for various cancers.
Product Name : CX-5461
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 14, 2024
Details:
(CX-5461 (pidnarulex), is a first-in-class small-molecule designed to stabilize G-quadruplex structures, which is being evaluated for the treatment of Solid Tumors.
Lead Product(s): Pidnarulex
Therapeutic Area: Oncology Brand Name: CX-5461
Study Phase: PreclinicalProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 17, 2024
Lead Product(s) : Pidnarulex
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Senhwa Submits IND for Pidnarulex Study in Advanced Solid Tumors Sponsored by NCI
Details : (CX-5461 (pidnarulex), is a first-in-class small-molecule designed to stabilize G-quadruplex structures, which is being evaluated for the treatment of Solid Tumors.
Product Name : CX-5461
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2024
Details:
CX-4945 (silmitasertib) is a first-in-class small molecule drug that acts as a CK2 inhibitor. It is being evaluated for the treatment of relapsed refractory solid tumors in children & young adults.
Lead Product(s): Silmitasertib
Therapeutic Area: Oncology Brand Name: CX-4945
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 08, 2024
Lead Product(s) : Silmitasertib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Senhwa Biosciences Gets FDA Study May Proceed Letter for Silmitasertib in Young Patients
Details : CX-4945 (silmitasertib) is a first-in-class small molecule drug that acts as a CK2 inhibitor. It is being evaluated for the treatment of relapsed refractory solid tumors in children & young adults.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 08, 2024
Details:
CX-4945 (silmitasertib) is a first-in-class small molecule CK2 inhibitor being evaluated for treating community-acquired pneumonia associated with viral infection.
Lead Product(s): Silmitasertib
Therapeutic Area: Infections and Infectious Diseases Brand Name: CX-4945
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2024
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Senhwa Doses First Patient in Phase II Study of Silmitasertib for Pneumonia
Details : CX-4945 (silmitasertib) is a first-in-class small molecule CK2 inhibitor being evaluated for treating community-acquired pneumonia associated with viral infection.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2024
Details:
CX-4945 (silmitasertib) is a first-in-class small molecule drug that targets the CK2 protein and acts as a CK2 inhibitor. It is being developed for the treatment of community-acquired pneumonia associated with viral infection.
Lead Product(s): Silmitasertib
Therapeutic Area: Infections and Infectious Diseases Brand Name: CX-4945
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2023
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-4945 (silmitasertib) is a first-in-class small molecule drug that targets the CK2 protein and acts as a CK2 inhibitor. It is being developed for the treatment of community-acquired pneumonia associated with viral infection.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 21, 2023
Details:
CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways. It is expected to be clinically effective against the community-acquired pneumonia caused by viral infection.
Lead Product(s): Silmitasertib
Therapeutic Area: Infections and Infectious Diseases Brand Name: CX-4945
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 19, 2023
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways. It is expected to be clinically effective against the community-acquired pneumonia caused by viral infection.
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2023
Details:
CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. It is expected to be clinically effective against the SARS-CoV-2 variants and other viruses.
Lead Product(s): Silmitasertib
Therapeutic Area: Infections and Infectious Diseases Brand Name: CX-4945
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 11, 2023
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. It is expected to be clinically effective against the SARS-CoV-2 variants an...
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 11, 2023
Details:
CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. It is expected to be clinically effective against the SARS-CoV-2 variants and other viruses.
Lead Product(s): Silmitasertib
Therapeutic Area: Infections and Infectious Diseases Brand Name: CX-4945
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 28, 2023
Lead Product(s) : Silmitasertib
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CX-4945 (silmitasertib) works by inhibiting CK2 protein kinase, which have implicated in regulation of several signaling pathways that are important for innate immune responses. It is expected to be clinically effective against the SARS-CoV-2 variants an...
Product Name : CX-4945
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2023
ABOUT THIS PAGE